Open AccessAnti‐tumor effect in an in vivo model by human‐derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties
Author(s) -
Yagi Hiroshi,
Ueda Masakazu,
Jinno Hiromitsu,
Aiura Koichi,
Mikami Shuji,
Tada Hiroko,
Seno Masaharu,
Yamada Hidenori,
Kitajima Masaki
Publication year - 2006
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2006.00336.x
Subject(s) - angiogenesis , in vivo , fusion protein , cancer research , basic fibroblast growth factor , growth factor , nude mouse , angiogenin , insulin like growth factor binding protein , fibroblast growth factor , biology , microbiology and biotechnology , chemistry , medicine , receptor , biochemistry , recombinant dna , insulin like growth factor , gene
It is thought that the export of angiogenic fibroblast growth factors (FGF) from tumors may be involved in the onset of tumor angiogenesis. To create a new active targeting drug that inhibits the tumor angiogenic process without toxicities to normal cells, human basic FGF (h‐bFGF) was inserted genetically into the Gly89 position of cross‐linked RNase1 (the ribonuclease inhibitor protein [RI] binding site of cross‐linked human pancreatic RNase) to prevent stereospecific binding to RI. The resultant insertional‐fusion protein (CL‐RFN89) was active both as h‐bFGF and as RNase1. Furthermore, it acquired an additional ability of evading RI through steric blockade of RI binding caused by the fused h‐bFGF domain. In the present study, the effect of the resultant protein, CL‐RFN89, on the antitumor response though its antiangiogenic properties was investigated in an in vivo model. Continuous systemic treatment with CL‐RFN89 significantly inhibited the growth of human A431 squamous cell carcinomas in vivo . Seven days of treatment with CL‐RFN89 resulted in a 58.2% inhibition of tumor growth compared with control mice ( P < 0.0001). Furthermore, immunohistochemistry using a rat antimouse CD31 antibody showed that treatment with CL‐RFN89 reduced tumor vascularization. These findings identify CL‐RFN89 as a potent systemic inhibitor of tumor growth as a result of its antiangiogenic properties. This protein appears to be a new systemic antitumor agent. ( Cancer Sci 2006; 97: 1315–1320)